Targeted drug with radiation therapy to preserve the bladder

Plain-English translation of NCT05833867 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new approach to treating muscle-invasive bladder cancer using , a targeted antibody drug that delivers cancer-killing medication directly to bladder cancer cells. The medication is combined with adaptive radiation therapy — advanced imaging-guided radiation that adjusts to your anatomy during treatment. The goal is to cure the cancer while keeping your bladder intact, rather than surgically removing it.

Many bladder cancer patients either cannot tolerate standard chemotherapy or prefer not to have their bladder surgically removed. This trial investigates whether this newer targeted medication might work better with fewer side effects than traditional chemotherapy when combined with radiation therapy.

Do you qualify?

You likely qualify if…

you have been diagnosed with muscle-invasive bladder cancer that has not spread beyond the bladder or nearby lymph nodes
you have not received any chemotherapy for this cancer before
you have refused, or are ineligible for, standard chemotherapy or bladder removal surgery
you are in generally good health with adequate organ and blood cell function
you have had a surgical procedure (TURBT) to remove the bladder tumor within the last 60 days

You likely don't qualify if…

you have already received chemotherapy for this bladder cancer
your cancer has spread to distant parts of your body or to multiple lymph nodes
you have significant problems with liver, kidney, or bone marrow function
you have another cancer outside the bladder that occurred in the past 2 years
your bladder is severely obstructed or damaged on both sides

What participation looks like

You would receive the medication intravenously (through a vein) over several treatment cycles lasting about 3 weeks each. One cycle happens before radiation begins, then two more cycles happen while you simultaneously receive adaptive radiation therapy to your bladder. The radiation is guided by imaging scans that adjust the treatment daily based on your anatomy, allowing doctors to target cancer cells precisely while protecting healthy tissue. You would have regular clinic visits for blood tests, imaging scans, and physical exams to monitor your response and watch for side effects.

AI-generated summary from trial data · Jun 24, 2026 · Not medical advice

Targeted drug with radiation therapy to preserve the bladder

What is this trial?

Do you qualify?

What participation looks like

Trial locations(1 site)